"Malaysia Pharmaceuticals & Healthcare Report Q4 2014" is now available at Fast Market Research

The Malaysian pharmaceutical and healthcare markets are set to grow significantly. Promising long-term economic growth, local government support, an ageing population and a surge of chronic non-communicable diseases , sector growth will continue to be driven . However, a slowdown in economic growth in 2014, coupled with the fact that investment in the pharmaceuticals sector will take longer than expected to bring returns, present downside risks to our outlook.

Headline Expenditure Projections

* Pharmaceuticals: MYR6.60bn (USD2.10bn) in 2013 to MYR7.51bn (USD2.35bn) in 2014; +13.7% in local currency and +12.0% in US dollar terms. Forecast increased from Q314 to better suit current market conditions.
* Healthcare: MYR40.27bn (USD12.78bn) in 2013 to MYR43.79bn (USD13.68bn) in 2014; +8.8% in local currency and +7.1% in US dollar terms. Forecast in line with last quarter's figures.

Full Report Details at
- http://www.fastmr.com/prod/888130_malaysia_pharmaceuticals_healthcare_report_q4.aspx?afid=302

Risk/Reward Rating: In Q414, Malaysia's Pharmaceutical Risk/Reward Rating (RRR) stood at 60, marking no change since Q114. It posts above-average scores for every indicator in the Asia Pacific region, and ranks eighth out of the 19 key markets.

Key Trends And Developments

August

In response to allegations that the MYR86mn (USD27.1mn) Halal hub project in Kiansam in Labuan, East Malaysia, was a mistake, former Labuan Member of Parliament Datuk Suhaili Abdul Rahman has stated that his successors are responsible for the failure of the project. 'The Halal hub was not born as a white elephant project but turned into one due to those responsible having strayed from the goal of using the hub for producing high-quality halal products,' said Suhaili (reports the Daily Express). The hub, which was initiated in 2009, aimed to add value to Labuan's marine products and cater for potential demand from the ASEAN and Gulf States. The project's plan also included processing of pharmaceuticals, herbs and cosmetics.

Malaysia, with a Muslim population of around 60%, aims to attract...

The Malaysia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Malaysia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Malaysian pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Malaysia to test other views - a key input for successful budgeting and strategic business planning in the Malaysian pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q4 2014
- Sweden Pharmaceuticals & Healthcare Report Q4 2014
- Kenya Pharmaceuticals & Healthcare Report Q4 2014
- Bulgaria Pharmaceuticals & Healthcare Report Q4 2014
- Argentina Pharmaceuticals & Healthcare Report Q4 2014